Patents by Inventor Gaël PETITJEAN

Gaël PETITJEAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR EVALUATING THE PRESENCE OF A VIRAL RESERVOIR, AND EVALUATING THE EFFICACY OF A DRUG AGAINST SAID RESERVOIR
    Publication number: 20210405026
    Abstract: A method for the evaluation of the efficacy of a drug aiming to eradicate a cellular reservoir of mammalian cells infected with a mammalian immunodeficiency virus, the method including: a) quantifying, the presence of lymphocyte cells expressing a CD32 differentiation marker on their surface; and b) concluding that the drug is efficient to eradicate the cellular reservoir of mammalian cells infected with the mammalian immunodeficiency virus when lymphocyte cells expressing a CD32a differentiation marker are absent.
    Type: Application
    Filed: August 18, 2021
    Publication date: December 30, 2021
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER
    Inventors: Monsef BENKIRANE, Gaël PETITJEAN, Benjamin DESCOURS
  • METHOD FOR EVALUATION THE PRESENCE OF A VIRAL RESERVOIR
    Publication number: 20210325391
    Abstract: A method for the evaluation of the efficacy of a drug aiming to eradicate a cellular reservoir of mammalian cells infected with a mammalian immunodeficiency virus, the method including: a) quantifying, the presence of lymphocyte cells expressing a CD89 differentiation marker on their surface; and b) concluding that the drug is efficient to eradicate the cellular reservoir of mammalian cells infected with the mammalian immunodeficiency virus when lymphocyte cells expressing a CD89 differentiation marker are absent.
    Type: Application
    Filed: May 7, 2021
    Publication date: October 21, 2021
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER
    Inventors: Monsef BENKIRANE, Gael PETITJEAN, Benjamin DESCOURS
  • Method for isolating HIV reservoir cells expressing CD32a cell marker
    Patent number: 11125751
    Abstract: The use of differentiation marker CD32 for the detection of cellular reservoirs of a mammalian immunodeficiency virus. Also the use of the differentiation marker CD32 for making a prognosis, diagnosing a remission, and evaluating the efficacy of treatment of the mammalian immunodeficiency. A multi-specific antibody that recognizes both at least one epitope of CD32 and at least one characteristic of the lymphocyte cells, a composition including the antibody, and the use of the antibody in treatment.
    Type: Grant
    Filed: September 30, 2017
    Date of Patent: September 21, 2021
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER
    Inventors: Monsef Benkirane, Gael Petitjean, Benjamin Descours
  • Cell identification method
    Patent number: 11054424
    Abstract: The present invention relates to the use of a nucleic acid molecule encoding a first reporter gene, bordered by at least one first pair and one second pair of sequences targeting a site-specific recombinase in order to detect cells of a mammal infected with a virus responsible for an immunodeficiency.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: July 6, 2021
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Monsef Benkirane, Gael Petitjean
  • Method for the detection of cells associated with the latent HIV viral reservoir using membrane biomarkers
    Patent number: 11041858
    Abstract: The use of differentiation marker CD89 for the detection of cellular reservoirs of a mammalian immunodeficiency virus. Also the use of the differentiation marker CD89 for making a prognosis, diagnosing a remission, and evaluating the efficacy of treatment of the mammalian immunodeficiency. A multi-specific antibody that recognizes both at least one epitope of CD89 and at least one characteristic of the lymphocyte cells, a composition including the antibody, and the use of the antibody for treatment.
    Type: Grant
    Filed: September 30, 2017
    Date of Patent: June 22, 2021
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER
    Inventors: Monsef Benkirane, Gael Petitjean, Benjamin Descours
  • CELL MARKERS
    Publication number: 20200031925
    Abstract: The use of differentiation marker CD32 for the detection of cellular reservoirs of a mammalian immunodeficiency virus. Also the use of the differentiation marker CD32 for making a prognosis, diagnosing a remission, and evaluating the efficacy of treatment of the mammalian immunodeficiency. A multi-specific antibody that recognizes both at least one epitope of CD32 and at least one characteristic of the lymphocyte cells, a composition including the antibody, and the use of the antibody in treatment.
    Type: Application
    Filed: September 30, 2017
    Publication date: January 30, 2020
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER
    Inventors: Monsef BENKIRANE, Gael PETITJEAN, Benjamin DESCOURS
  • MEMBRANE MARKERS
    Publication number: 20190219577
    Abstract: The use of differentiation marker CD89 for the detection of cellular reservoirs of a mammalian immunodeficiency virus. Also the use of the differentiation marker CD89 for making a prognosis, diagnosing a remission, and evaluating the efficacy of treatment of the mammalian immunodeficiency. A multi-specific antibody that recognizes both at least one epitope of CD89 and at least one characteristic of the lymphocyte cells, a composition including the antibody, and the use of the antibody for treatment.
    Type: Application
    Filed: September 30, 2017
    Publication date: July 18, 2019
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER
    Inventors: Monsef BENKIRANE, Gael PETITJEAN, Benjamin DESCOURS
  • CELL IDENTIFICATION METHOD
    Publication number: 20170350889
    Abstract: The present invention relates to the use of a nucleic acid molecule encoding a first reporter gene, bordered by at least one first pair and one second pair of sequences targeting a site-specific recombinase in order to detect cells of a mammal infected with a virus responsible for an immunodeficiency.
    Type: Application
    Filed: December 17, 2015
    Publication date: December 7, 2017
    Applicant: Centre National De La Recherche Scientifique (CNRS)
    Inventors: Monsef Benkirane, Gael Petitjean